9 Meters Biopharma Acquires Anti-GIP Monoclonal Antibody For Obesity-Related Disorders

  • 9 Meters Biopharma Inc NMTR has acquired global development rights to LOB-0136 (now known as NM-136) that targets glucose-dependent insulinotropic polypeptide (GIP) from Lobesity LLC.
  • GIP is a hormone whose concentration increases significantly with overeating, leading to higher glucose absorption and greater insulin release. These changes lead to increased glucose uptake into fat cells, contributing to obesity and obesity-related disorders such as Prader-Willi Syndrome (PWS). 
  • NM-136, an anti-GIP humanized monoclonal antibody. 
  • 9 Meters plans to continue the manufacturing optimization and IND-enabling studies and conduct a clinical proof-of-concept study in PWS in 2023.
  • Deal consideration includes 40% cash and 60% equity consideration in the form of a $5 million upfront payment, plus contingent payments of up to $45.5 million, global sales-related milestone payments totaling up to $50 million, and a mid-single-digit sales royalty.
  • Price Action: NMTR shares are down 1.39% at $1.065 during the market session on the last check Monday.

Posted In: BriefsobesityBiotechM&ANewsPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.